New York University

The NYU Langone Center for Psychedelic Medicine performs health-focused research across the translational spectrum, from basic science to large-scale clinical trials. The center has three main focus areas regarding psychedelic science; psychiatry, medicine and pre-clinical research. The center will be directed by Dr. Michael P. Bogenschutz who is no stranger to psychedelic research, having been involved in numerous trials exploring psychedelics for various disorders.

A number of well-known individuals and companies in the psychedelic space invested in excess of $10 million in the development of the new center at NYU. These include MindMed, Heffter Research Institute president Carey Turnbull, Pennant Investors founder Alan Fournier, Usona Institute president Bill Linton, and Dr. Bronner’s Soaps, among others. MindMed made the largest contribution donating over $5 million to the cause.

Company Information

New York University Website

Founded
January, 1970

Operational
Yes

Activities
Research Institute

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Company News

UAB researcher granted federal funding for psilocybin and smoking study (UAB News, 01 March 2024)
Researchers at the University of Alabama at Birmingham, Johns Hopkins University and New York University were awarded nearly $4 million in funding to study the efficacy of psilocybin.

Location

HQ / Office 550 1st Ave, New York, NY 10016, USA